Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Versanis Bio has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in August 2021.
Versanis Bio's investors include TCG Crossover, Atlas Venture, Medicxi, Aditum Bio.
Versanis Bio is headquartered in Oakland, United States.
Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.
Versanis Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Versanis Bio — Funding & Investors." VCBacked, August 31, 2021, https://www.vcbacked.co/company/versanis-bio. Accessed August 16, 2026.
VCBacked. (2021). Versanis Bio — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/versanis-bio
{{cite web |title=Versanis Bio — Funding & Investors |url=https://www.vcbacked.co/company/versanis-bio |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated